Drugs / ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07290946 | Dec 2025 → Jun 2027 expected | Sjogren syndrome | Christian von Buchwald | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07290946 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells are administered” NCT07290946 ↗ |
| Route | Other | “intraglandular injections in both submandibular glands” NCT07290946 ↗ |